Tag : SPESOLIMAB

Spesolimab demonstrated rapid resolution of recurrent flares in generalized pustular psoriasis (GPP), based on preliminary findings from the ongoing EFFISAYIL-REP study. Within one week, 66.7% of patients achieved pustular clearance, with this rate increasing to 80.6% by week two.